Ming H, Sha L, Hor YT, Ning W, Sai WT, Yibin F. Current status of herbal medicines in chronic liver disease therapy: the biological effects, molecular targets and future Prospects. Int J Mol Sci 2015;16:28705–45.CrossrefPubMedWeb of ScienceGoogle Scholar
Del PA, Scalera A, Iadevaia MD, Miranda A, Zulli C, Gaeta L, et al. Herbal products: benefits, limits, and applications in chronic liver disease. Evid Based Complement Altern Med 2012;2012:837939.Web of ScienceGoogle Scholar
Girish C, Bidhan CK, Jayanthib S, Ramachandra KR, Rajesh B, Suresh CP. Hepatoprotective activity of six polyherbal formulations in CCl4-induced liver toxicity in mice. Indian J Exp Biol 2009;47:257–63.PubMedGoogle Scholar
El-Shenawy SM, Hassan NS. Comparative evaluation of the protective effect of selenium and garlic against liver and kidney damage induced by mercury chloride in the rats. Pharmacol Rep 2008;60:199–208.PubMedGoogle Scholar
Subramoniam A, Pushpangadan P. Development of phytomedicines for liver diseases. Indian J Pharmacol 1999;31:166–75.Google Scholar
Kupeli E, Orhan DD, Yesilada E. Effect of Cistus laurifolius L. leaf extracts and flavonoids on acetaminophen-induced hepatotoxicity in mice. J Ethnopharmacol. 2006;103:455–60.CrossrefPubMedGoogle Scholar
Evans WC. An overview of drugs having antihepatotoxic and oral hypoglycaemic activities. In: Trease and Evans’ WC, eds. Phamacognosy, 14th ed. UK: W.D. Sanders Company Ltd, 1996.Google Scholar
Gupta V, Bansal P, Bansal R, Kumar S. Value addition by standardization of herbal drugs at global level – a review. Arch Pharm Sci Res 2010;2:326–30.Google Scholar
Ayurvedic Formulary of India, Part I & II. Department of AYUSH, Ministry of Health & Family Welfare, New Delhi, Government of India; 2005.Google Scholar
Gupta V, Bansal P, Kumar S, Bansal R, Meena AK, Sharma S. Chromatographic techniques in standardization of herbal drugs – a review. J Punjab Acad Sci 2010;5–6:24–30.Google Scholar
Meena AK, Bansal P, Kumar S. Herbal wealth as a potential source of ayurvedic drugs. Asian J Tradit Med 2009;4:152–70.Google Scholar
Ghosh A, Kundu A, Seth A, Singh AK, Maurya SK. Preliminary evaluation of hepatoprotective potential of the polyherbal formulation. J Intercult Ethnopharmacol 2015;4:118–24.PubMedWeb of ScienceCrossrefGoogle Scholar
Seth SD, Sharma B. Medicinal plants of India. Ind J Med Res 2004;120:9–11.Google Scholar
Handa SS, Sharma A, Chakraborty KK. Natural products and plants as liver protecting drugs. Fitoterapia 1989;57:307–51.Google Scholar
Hikino H, Kiso Y. Natural products for liver diseases. In: H. Wagner, Hiroshi Hikino, Norman Farnsworth, eds. Economic and medicinal plant research, vol. 2. London: Academic Press, 1988:39-72.Google Scholar
Doreswamy R, Sharma D. Plant drugs for liver disorders management. Indian Drugs. 1995;32:139–44.Google Scholar
Wang T, Sun NL, Zhang WD, Li HL, Lu GC, Yuan BJ, et al. Protective effects of dehydrocavidine on carbon tetrachloride-induced acute hepatotoxicity in rats. J Ethnopharmacol 2008;117:300–8.PubMedWeb of ScienceCrossrefGoogle Scholar
ICH guidelines, Analytical method validation (Q3). Geneva, 2000.Google Scholar
ICH. Validation of analytical procedures and methodology, in Proceedings of the International Conference on Harmonization, Geneva, Switzerland, 2005.Google Scholar
Pharmacopoeia U.S. USP-NF <1225> Validation of Compendial Methods. USP 32-NF27. 2009.Google Scholar
FDA guidance for industry, Analytical procedure and method validation for drugs and biologics, Food and Drug administrator, 2015.Google Scholar
Pasbola K, Chaudhary M. Updated review on analytical method development and validation by HPLC. World J Pharm Pharm Sci 2017;6:1612–30.Google Scholar
Belouafa S, Habti F, Benhar S, Belafkih B, Tayane S, Hamdouch S, et al. Statistical tools and approaches to validate analytical methods: methodology and practical examples. Int J Metrol Qual Eng 2017;8:1–10.Google Scholar
About the article
Published Online: 2019-03-13
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
Conflict of interest: None declared.